Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Anticancer Ther. 2015 Feb;15(2):199-205. doi: 10.1586/14737140.2015.978861. Epub 2014 Nov 5.

Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI.

Author information

1
The Russell H. Morgan Department of Radiology and Radiological Sciences, Division of Vascular and Interventional Radiology, The Johns Hopkins Hospital, Johns Hopkins University School of Medicine, 1800 Orleans Street, Sheikh Zayed Tower, Suite 7203, Baltimore, MD 21287, USA.

Abstract

Assessing the tumor response of liver cancer lesions after intraarterial therapies is of major clinical interest. Over the last two decades, tumor response criteria have come a long way from purely size-based, anatomic methods such as the Response Evaluation Criteria in Solid Tumors towards more functional, enhancement- and diffusion-based parameters with a strong emphasis on MRI as the ultimate imaging modality. However, the relatively low reproducibility of those one- and 2D techniques (modified Response Evaluation Criteria in Solid Tumors and the European Association for the Study of the Liver criteria) provided the rationale for the development of new, 3D quantitative assessment techniques. This review will summarize and compare the existing methodologies used for 3D quantitative tumor analysis and provide an overview of the published clinical evidence for the benefits of 3D quantitative tumor response assessment techniques.

KEYWORDS:

3D; ADC; MRI; RECIST; intraarterial therapy; liver cancer; qEASL; quantitative imaging; tumor response

PMID:
25371052
PMCID:
PMC4304995
DOI:
10.1586/14737140.2015.978861
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center